Next report date
Report period
Q1 2024
EPS estimate
−0.57USD
Revenue estimate
—
−2.17USD
−19.51 MUSD
9.34 M
About Imunon, Inc.
Sector
Industry
Headquarters
Lawrenceville
Website
Employees (FY)
33
Founded
1982
FIGI
BBG000BJJGT8
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMNN is 1.44 USD — it has increased by 10.77% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Imunon, Inc. stocks are traded under the ticker IMNN.
Imunon, Inc. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
IMNN stock is 14.29% volatile and has beta coefficient of 1.50. Check out the list of the most volatile stocks — is Imunon, Inc. there?
IMNN earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.66 USD resulting in a 43.94% surprise. The estimated earnings for the next quarter are −0.59 USD per share. See more details about Imunon, Inc. earnings.
Imunon, Inc. revenue for the last quarter amounts to 125.00 K USD despite the estimated figure of 116.67 K USD. In the next quarter revenue is expected to reach 62.50 K USD.
Yes, you can track Imunon, Inc. financials in yearly and quarterly reports right on TradingView.
IMNN stock has risen by 25.22% compared to the previous week, the month change is a 54.84% rise, over the last year Imunon, Inc. has showed a 25.28% increase.
IMNN net income for the last quarter is −4.89 M USD, while the quarter before that showed −3.48 M USD of net income which accounts for −40.60% change. Track more Imunon, Inc. financial stats to get the full picture.
Today Imunon, Inc. has the market capitalization of 13.54 M, it has decreased by 7.30% over the last week.
No, IMNN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMNN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Imunon, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 33.00 employees. See our rating of the largest employees — is Imunon, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Imunon, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Imunon, Inc. stock shows the sell signal. See more of Imunon, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Imunon, Inc. future price: according to them, IMNN price has a max estimate of 15.00 USD and a min estimate of 8.00 USD. Read a more detailed Imunon, Inc. forecast: see what analysts think of Imunon, Inc. and suggest that you do with its stocks.